Table 1 Demographic and clinical characteristics of the study participants
From: Distinct effects of cholesterol profile components on amyloid and vascular burdens
Total (n = 1125) | CU (n = 456) | MCI (n = 719) | p | |
|---|---|---|---|---|
Demographics | ||||
Age, years | 70.8 ± 8.2 | 70.6 ± 8.1 | 70.9 ± 8.2 | 0.557 |
Middle-aged, ≤ 65 years | 272 (23.1%) | 103 (22.6%) | 169 (23.5%) | 0.770 |
Gender, females | 641 (54.6%) | 268 (58.8%) | 373 (51.9%) | 0.024 |
Education, years | 12.5 ± 4.7 | 12.2 ± 4.7 | 12.2 ± 4.7 | 0.909 |
Clinical characteristics | ||||
APOE e4 carrier | 446 (38.0%) | 128 (28.1%) | 318 (44.2%) | < 0.001 |
Hypertension | 530 (45.1%) | 213 (46.7%) | 317 (44.1%) | 0.412 |
Diabetes | 233 (19.8%) | 94 (20.6%) | 139 (19.3%) | 0.644 |
Lipid-lowering medication | 368 (31.3%) | 138 (30.3%) | 230 (32.0%) | 0.578 |
AChE inhibitor | 647 (55.1%) | 113 (24.8%) | 534 (74.3%) | < 0.001 |
Memantine | 70 (6.0%) | 13 (2.9%) | 57 (7.9%) | 0.001 |
Cholesterol | ||||
LDL-c | 109.2 ± 35.1 | 107.6 ± 33.9 | 110.2 ± 35.8 | 0.208 |
HDL-c | 58.6 ± 16.7 | 59.1 ± 16.4 | 58.3 ± 16.9 | 0.382 |
Triglyceride | 118.5 ± 55.9 | 120.0 ± 53.6 | 117.6 ± 57.3 | 0.477 |
Imaging markers | ||||
Aβ uptake, dcCL | 39.8 ± 46.7 | 20.0 ± 34.6 | 52.3 ± 49.0 | < 0.001 |
WMH volume, mL | 5.27 ± 9.33 | 4.64 ± 10.26 | 5.69 ± 8.66 | 0.085 |
HV, mL | 2.78 ± 0.5 | 2.98 ± 0.4 | 2.65 ± 0.5 | < 0.001 |